Understanding the shift
Four growth pathways
of all deals over the past 10 years were Builder and Architect pathways, but the traditional Builder pathways approach is becoming less appealing.
increase in Architect pathways over the past five years compared to the previous five year period.
of the total volume of M&A deals focus on Ecosystem pathways.
of deals focus on geographic expansion or vertical integration (Controller pathways).
Deals announced early in 2022 support our predictions. Sanofi’s collaboration with Exscientia, an AI-drug discovery company, is an example of the Ecosystem pathway whereas Pfizer’s with Beam Therapeutics is an example of the Architect pathway.
Where does the analysis take us?
Visit our Subscription and Preference Center